TITLE
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in pre-clinical models of aggressive lymphomas

ORGANISM
Homo sapiens

SUMMARY
assess the efficacy of Pimasertib to characterize its mechanism of action

DESIGN
GEP analysis of one lymphoma cell line with and without treatment with Pimasertib

PLATFORM
GPL10558 Illumina HumanHT-12 V4.0 expression beadchip

CITATIONS
26961147

